Skip to main content
. 2019 Oct 1;8(10):1569. doi: 10.3390/jcm8101569

Table 1.

Patient characteristics, iron status, biomarker levels, and diastolic function indices on transthoracic echocardiography (TTE), according to heart failure category.

Total Cohort HFrEF,
160 (33%)
HFpEF,
270 (55%)
p-Value
Baseline characteristics
  LVEF (%) 48 ± 16 27 ± 6 60 ± 6 <0.001 *
  Age, year 78 ± 11 75 ± 12 80 ± 10 <0.001*
  Female sex, n (%) 217 (43%) 48 (30%) 141 (52%) <0.001 *
  NYHA class, I/II/III/IV (%) 2/6/37/55 1/7/40/52 1/7/38/54 0.97
  Length of stay, days 11 ± 9 11 ± 8 10 ± 8 0.34
  Coronary artery disease, n (%) 177 (36%) 65 (42%) 83 (32%) 0.054
  Hypertension, n (%) 393 (79%) 111 (70%) 223 (84%) <0.001 *
  Diabetes mellitus, n (%) 157 (31%) 47 (30%) 87 (32%) 0.61
  Obesity, n (%) 231 (47%) 69 (45%) 130 (49%) 0.49
  Active/past smoker, n (%) 288 (60%) 106 (68%) 145 (56%) 0.019 *
  Chronic kidney disease, n (%) 175 (36%) 49 (31%) 105 (40%) 0.081
  Atrial fibrillation or flutter, n (%) 222 (45%) 58 (36%) 132 (50%) 0.01 *
  COPD, n (%) 73 (15%) 21 (14%) 38 (16%) 0.61
Iron studies
  Iron deficiency, n (%) 239 (57%) 73 (54%) 123 (56%) 0.88
  Absolute iron deficiency, n (%) 165 (38%) 49 (37%) 82 (41%) 0.64
  Functional iron deficiency, n (%) 74 (18%) 24 (18%) 30 (15%) 0.61
  Haemoglobin level, g/mL 123 ± 23 129 ± 20 121 ± 23 <0.001 *
Biomarker levels
  CRP, mg/L 11.4 ± 27.6 9.4 ± 19.8 12.1 ± 31.5 0.064
  BNP, ng/L 857 ± 885 1279 ± 974 648 ± 687 <0.001 *
  NT-proBNP, pg/mL 3926 ± 6763 7340 ± 8020 2695 ± 5171 <0.001 *

COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; BMI, body mass index; LV, left ventricle; LVMI, left ventricular mass index; LAVI, left atrial volume index; RVSP, right ventricular systolic pressure; TTE, transthoracic echocardiography; RVSP, right ventricular systolic pressure; CRP, C-reactive protein, BNP, brain natriuretic peptide, NT-proBNP, N-terminal prohormone of BNP. * denotes p-value less than the significance threshold of <0.05.